PhRMA, National Osteoporosis Foundation team on pipeline report

WASHINGTON — The National Osteoporosis Foundation and the Pharmaceutical Research and Manufacturers of America have teamed up on a new report covering the current state of the pipeline for osteoporosis drugs. 

 

The study found that there are currently nine medicines being developed, including five for postmenopausal osteoporosis, two for drug-induced osteoporosis and two specifically for men with osteoporosis. Additionally, there are 34 ongoing clinical trials studying osteoporosis treatments. 

 

“We are pleased to see that there continues to be progress made in the development of treatments for osteoporosis, but as our aging population continues to grow, there is more work to be done for patients,” PhRMA president and CEO Stephen J. Ubl said. “With 3 million bone fractures expected a year by 2025, biopharmaceutical companies are committed to advancing osteoporosis research and discovering new treatment options to help patients live longer, healthier lives.”

 

Osteoporosis affects nearly 54 million Americans, and by 2030 that number is expected to grow to more than 71 million people. Osteoporosis-caused broken bones affect half of women and a quarter of men over the age of 50. 

 

“We are encouraged by advancements in the research and development of treatments for osteoporosis,” National Osteoporosis Foundation president Dr. Robert F. Gagel. “New treatments and prevention efforts provide hope for a future in which fewer Americans suffer from the pain and disability this disease causes.”